News & Media
Learn more about the latest happenings at Otsuka. Select to see US news or read our press releases. You can also stay up to date with our global news in the link below.
Media Contact:
Senior Director, External Communications,
Otsuka America Pharmaceutical, Inc
Otsuka America Pharmaceutical, Inc. and Otsuka Pharmaceutical Development & Commercialization, Inc. (Otsuka) are pleased that the United States Senate has passed the combined version of the 21st Century Cures Act, the Helping Families in Mental Health Crisis Act, and the Mental Health and Safe Communities Act (H.R. 34), following recent passage by the House of Representatives. We applaud the
Phase III investigational study results present efficacy, tolerability and safety profile of long-acting injectable aripiprazole (ABILIFY MAINTENA®) in maintenance treatment of bipolar I disorder1Study data demonstrate long-acting injectable aripiprazole (ABILIFY MAINTENA) delayed time to recurrence of mood episodes in recently manic patients, as compared with placebo1 PRINCETON, N.J.
Otsuka America Pharmaceutical, Inc. and Otsuka Pharmaceutical Development & Commercialization, Inc. (Otsuka) are pleased that the United States House of Representatives has passed the combined version of the 21st Century Cures Act, the Helping Families in Mental Health Crisis Act, and the Mental Health and Safe Communities Act (H.R. 34). We applaud the leadership in the House of
Application seeks to expand ABILIFY MAINTENA label to include maintenance treatment for bipolar I disorder If the label expansion is approved, ABILIFY MAINTENA would offer prescribers a once-monthly long-acting injectable treatment option in the maintenance treatment of bipolar I disorder in adults (TOKYO, Japan & VALBY, Denmark, November 30, 2016) – Otsuka Pharmaceutical Co., Ltd.